Moderna Stock

Is Moderna (MRNA) Stock Worth Buying After Announcing Plans To Increase Global Supply For COVID-19 Vaccine To 3 Billion Doses By 2022?

Moderna (NASDAQ: MRNA) stock was down by 1.68% at close Thursday. Those Investors who focused on the biopharmaceutical stocks were not excited about this news that published by the company on Wednesday. - April 30, 2021

Will Moderna and Novavax Stocks Rise About A UK Research?

The trial currently is being expanded its vaccine candidate range, including Moderna's and Novavax's COVID-19 vaccines. - April 14, 2021

MRNA Stock: Is Moderna Stock Worth A Buy Now?

Moderna still has a chance to generate strong revenue from its COVID-19 vaccine even if the pandemic is over. - April 11, 2021

Covid-19 Vaccine Orders Are Piling Up, Moderna Stock Has Room to Grow

With production ramping up to 1.4 billion doses and next-gen vaccine in trials, don’t underestimate Covid-19 vaccine upside for MRNA stock. - March 25, 2021

Even Moderna Can Be a Penny Stock with Fractional Shares | The Motley Fool

New trading platform functionality has made expensive stocks accessible. - March 19, 2021

Has Moderna Stock Already Peaked? | The Motley Fool

The vaccine maker's shares have fallen sharply in the past month as investors appear to be moving away from COVID-19 stocks. - March 18, 2021

Why Moderna Stock Is Slipping Today | The Motley Fool

Investors appear to be skittish about the Fed's meeting today. - March 17, 2021

Why Moderna Stock Climbed Today | The Motley Fool

The biotech is testing a "next-generation" coronavirus vaccine. - March 15, 2021

Before You Buy Moderna, Stop and Consider These 3 Things | The Motley Fool

The future is bright, but significant uncertainty remains. - March 14, 2021

The Better Stock for 2021: Moderna or Novavax? | The Motley Fool

The wisdom of crowds may give us the answer. - March 14, 2021

Is Johnson & Johnson's COVID Vaccine Actually Better Than Pfizer's and Moderna's Vaccines? | The Motley Fool

Don't jump to any conclusions based on the different vaccines' advisory committee votes. - March 13, 2021

Was AstraZeneca Smart to Sell Its Moderna Shares? | The Motley Fool

It's a definite maybe. - March 13, 2021

How Does Johnson & Johnson's COVID Vaccine Approval Affect Moderna? | The Motley Fool

Not much -- at least for now. - March 12, 2021

Why Moderna Stock Surged Today | The Motley Fool

The biotech is searching for ways to offer a greater defense against new coronavirus mutations. - March 11, 2021

Moderna Looks for a Breakout in 2021 | The Motley Fool

But 2022 is likely to be the year that defines the company. - March 10, 2021

Meet Moderna's Surprising New COVID Vaccine Partner | The Motley Fool

Hint: It's a company that's a lot bigger and that's been around a lot longer than Moderna. - March 10, 2021

Should You Buy Moderna in March? | The Motley Fool

The stock is down big, but the company is coming off of an improved fourth quarter. - March 10, 2021

Moderna and Pfizer's Second-Gen Coronavirus Vaccines: What Investors Need to Know | The Motley Fool

The competitive landscape is flattening out. - March 07, 2021

Why Moderna Was a Roller Coaster Today | The Motley Fool

Several bits of news were buffeting the stock in various directions. - March 05, 2021

Why Moderna Stock Is Down 25% Over The Last Month

Moderna stock has declined by about 25% over the last month and by close to 17% over the last two trading days alone. So what’s driving the sell-off? Firstly, rising bond yields have taken some sheen off growth stocks such as Moderna in recent weeks. Secondly, rival Johnson & Johnson... - March 05, 2021

Why Moderna Could Be Worth $100 Billion Within 5 Years | The Motley Fool

It's more achievable than you might think. - March 04, 2021

Why Moderna Stock Is Sinking Again Today | The Motley Fool

Investors appear to be jittery about good news for rival COVID-19 vaccines. - March 03, 2021

AstraZeneca Just Sold Its Moderna Stock: Should You? | The Motley Fool

Don't be too quick to pull the trigger. - March 03, 2021

Moderna's CEO Calls These 3 Elements "Critical" for Vaccine Success | The Motley Fool

And he says Moderna has them. - March 03, 2021

Here's How Moderna Is Ensuring Its Lead in the Coronavirus Vaccine Market | The Motley Fool

The biotech's recent earnings report offered a few clues. - March 02, 2021

Why Moderna Stock Is Slipping Today | The Motley Fool

Blame it on Johnson & Johnson. - March 01, 2021

What's the Strongest Buy: Moderna, Teladoc Health, or Fulgent Genetics? | The Motley Fool

All three of these stocks have had incredible spikes because of COVID-19. One stock, however, is a safer and stronger long-term investment. - February 26, 2021

Moderna Earnings: What Happened

Moderna (MRNA) reported Q4 earnings before market open on February 25. It reported another loss per share as revenue beat expectations. - February 26, 2021

Is There a Future for Moderna Beyond COVID-19? | The Motley Fool

What does Moderna's future look like aside from its COVID-19 vaccine program? - February 25, 2021